Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Divestments (2020)

Theravance Biopharma (TBPH) has disclosed Divestments for 2 consecutive years, with -$1.1 billion as the latest value for Q4 2022.

  • On a quarterly basis, Divestments changed N/A to -$1.1 billion in Q4 2022 year-over-year; TTM through Dec 2022 was -$1.1 billion, a N/A change, with the full-year FY2022 number at $2.7 million, changed N/A from a year prior.
  • Divestments was -$1.1 billion for Q4 2022 at Theravance Biopharma, down from $14.9 million in the prior quarter.
  • In the past five years, Divestments ranged from a high of $14.9 million in Q1 2020 to a low of -$1.1 billion in Q4 2022.